Christopher H. Yoo
A5050427212- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- Lymphoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Genomics, phytochemicals, and oxidative stress
- Sarcoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Genetic factors in colorectal cancer
- Acute Lymphoblastic Leukemia research
- Glutathione Transferases and Polymorphisms
- Musculoskeletal synovial abnormalities and treatments
- Ferroptosis and cancer prognosis
- Childhood Cancer Survivors' Quality of Life
- Hematopoietic Stem Cell Transplantation
- Plant and Fungal Interactions Research
- Viral-associated cancers and disorders
- Cancer-related cognitive impairment studies
- Flow Experience in Various Fields
- Vascular Malformations Diagnosis and Treatment
Stanford University
2018-2024
Washington University in St. Louis
2024
Cancer Institute (WIA)
2024
Saint Louis University
2021-2022
Stratford University
2020
Stanford Cancer Institute
2019
Duke University
2019
Institut des Sciences Cognitives Marc Jeannerod
2019
Stanford Medicine
2018
Lucile Packard Children's Hospital
2018
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple types, but whether further can improve outcomes patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 consolidation immune checkpoint inhibition (CICI). Patients undetectable after CRT had excellent or not they received CICI. Among such...
Tumor genotyping is not routinely performed in localized non-small cell lung cancer (NSCLC) due to lack of associations mutations with outcome. Here, we analyze 232 consecutive patients NSCLC and demonstrate that KEAP1 NFE2L2 are predictive high rates local recurrence (LR) after radiotherapy but surgery. Half LRs occurred tumors KEAP1/NFE2L2 mutations, indicating they major molecular drivers clinical radioresistance. Next, functionally evaluate our cohort only pathogenic associated...
Treatment with PD-(L)1 blockade can produce remarkably durable responses in patients non-small cell lung cancer (NSCLC). However, a significant fraction of long-term responders ultimately progress and predictors late progression are unknown. We hypothesized that circulating tumor DNA (ctDNA) analysis to may differentiate those who will achieve ongoing benefit from at risk eventual progression.In advanced NSCLC achieving (progression-free survival ≥ 12 months), plasma was collected...
Abstract Background Few studies have addressed the efficacy of palliative radiotherapy (RT) for pediatric osteosarcoma (OS), a disease generally considered to be radioresistant. We describe symptom relief, local control, and toxicity associated with RT among children OS. Procedure Patients diagnosed OS at age 18 under treated palliation symptomatic metastases or recurrence primary site from 1997 2017 were included. retrospectively reviewed details RT, improvement, survival, toxicity. Results...
Abstract Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring the neoplastic processes of central nervous system. We applied lung cancer-specific sequencing panel (CAPP-Seq) to 81 CSF, blood, and tissue samples from 24 cancer patients who underwent lumbar puncture (LP) suspected leptomeningeal disease (LMD). A subset cohort ( N = 12) participated in prospective trial osimertinib refractory LMD which serial LPs were performed before during...
Purpose: To evaluate outcomes and central nervous system (CNS) relapse in adolescents young adults (AYAs) with acute lymphoblastic leukemia (ALL), who underwent total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (allo-SCT). Methods: A of 136 AYA patients ALL received TBI allo-SCT between 1998 2018 were reviewed. Twenty cranial radiation their initial treatment conditioning for transplant excluded. Competing risk analysis was used to estimate the cumulative...
Abstract Introduction Cerebrospinal fluid tumor-derived DNA (CSF-tDNA) analysis is a promising approach for monitoring neoplastic processes of the central nervous system. We hypothesize that CSF-tDNA in patients with advanced lung cancer improves sensitivity leptomeningeal disease (LMD) diagnosis and enables system response monitoring. Methods applied CAPP-Seq using cancer-specific sequencing panel to 81 CSF, blood, tissue samples from 24 who underwent lumbar puncture (LP) suspected LMD. A...
<div>AbstractPurpose:<p>Treatment with PD-(L)1 blockade can produce remarkably durable responses in patients non–small cell lung cancer (NSCLC). However, a significant fraction of long-term responders ultimately progress and predictors late progression are unknown. We hypothesized that circulating tumor DNA (ctDNA) analysis to may differentiate those who will achieve ongoing benefit from at risk eventual progression.</p>Experimental Design:<p>In advanced NSCLC...
Here we describe the case of a 10-year-old boy with history chronic hepatitis B who was diagnosed hepatocellular carcinoma (HCC) large central hepatic mass and metastatic disease in celiac lymph node. His tumor unresectable, due to location lack clear margins, he could not receive chemotherapy elevated bilirubin. He treated stereotactic body radiotherapy (SBRT) primary site involved nodal region. After completing radiotherapy, his total bilirubin level fell below 1.0 mg/dL, allowing him...
The present study examined associations between physical activity, sleep, and academic outcomes in undergraduate students (N = 52). More consistent sleep throughout the semester (lower variability) was associated with higher homework grades. interaction variability quantity not significant suggesting that greater overall did buffer from negative effects of on
We set to identify prognostic factors in a retrospective cohort of consecutive patients with stage I-II diffuse large B-cell lymphoma treated rituximab-chemotherapy or without radiotherapy from 2001 through 2017 at our institution. identified 143 median follow-up 7.7 years. The majority were male (59.4%), had II (53.1%), stage-modified IPI 0–1 (smIPI, 58.1%), and non-bulky disease (<7 cm, 68.5%). 99 (69.2%) received followed by radiotherapy, 44 (30.8%) alone. 5-year progression-free survival...
We describe a case of 48-year-old woman with refractory cutaneous CD30 positive lymphoproliferative disorder treated successfully total skin electron beam radiotherapy (TSEBT).
<p>Table S1 shows summary patient demographics, pathologic features, and treatment details</p>
<p>Supplementary Data Legends.</p>
<p>Supplementary Figures related to 1, 2, 3, and 4.</p>
<p>Table S1 shows summary patient demographics, pathologic features, and treatment details</p>
<p>Supplementary Data Legends.</p>
<p>Supplementary Figures related to 1, 2, 3, and 4.</p>
<div>AbstractPurpose:<p>Treatment with PD-(L)1 blockade can produce remarkably durable responses in patients non–small cell lung cancer (NSCLC). However, a significant fraction of long-term responders ultimately progress and predictors late progression are unknown. We hypothesized that circulating tumor DNA (ctDNA) analysis to may differentiate those who will achieve ongoing benefit from at risk eventual progression.</p>Experimental Design:<p>In advanced NSCLC...